Mechanism of action in obesity R&D pipeline worldwide 2024

Statista2026-04-11 收录

抗肥胖药物研发

作用机制

数据链接：

https://www.statista.com/statistics/1554307/assets-in-obesity-pipeline-by-mechanism-of-action/数据链接链接失效反馈

官方服务：

资源简介：

Number of assets in next-generation obesity R&D pipeline worldwide as of 2024, by mechanism of action

Hsp90 Blockers Inhibit Adipocyte Differentiation and Fat Mass Accumulation

抗肥胖药物研发

脂肪细胞分化

Geldanamycin derivatives are benzoquinone ansamycin antibiotics that bind to Hsp90 and alter its function. The alteration of Hsp90 activity limits some cellular hormonal responses by inhibiting nuclea

NIAID Data Ecosystem70

Elaiophylin reduces body weight and lowers glucose levels in obese mice by activating AMPK

抗肥胖药物研发

AMPK代谢调控

Obesity is an epidemic affecting 13% of the global population and increasing the risk of many chronic diseases. However, only several drugs are licensed for pharmacological intervention for the treatm

NIAID Data Ecosystem20

Design, Synthesis, and Biological Evaluation of a Novel Series of 4‑Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low Systemic Exposure for the Treatment of Obesity

肠肽酶抑制剂

抗肥胖药物研发

To discover a novel series of potent inhibitors of enteropeptidase, a membrane-bound serine protease localized to the duodenal brush border, 4-guanidinobenzoate derivatives were evaluated with minimal

NIAID Data Ecosystem20

Design, Synthesis, and Biological Evaluation of a Novel Series of 4‑Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low Systemic Exposure for the Treatment of Obesity

肠肽酶抑制剂开发

抗肥胖药物研发

NIAID Data Ecosystem40

Targeting FoxO1 with AS1842856 Suppresses Adipogenesis

脂肪生成

抗肥胖药物研发

Hyperplasia (i.e., increased adipogenesis) contributes to excess adiposity, the hallmark of obesity that can trigger metabolic complications. As FoxO1 has been implicated in adipogenic regulation, we

Taylor & Francis Group2023-06-28 更新20

Mechanism of action in obesity R&D pipeline worldwide 2024

资源简介：

相关数据集